Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin + fluorouracil + irinotecan + leucovorin + bevacizumab
- Development stage
- Unknown
- Lead developer
- City of Hope Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
This investigational combination therapy involves the regional delivery of mitomycin C via pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in conjunction with systemic FOLFIRI (fluorouracil, irinotecan, and leucovorin) and bevacizumab. Developed by City of Hope Medical Center, this approach is designed to treat unresectable peritoneal metastases arising from appendiceal or colorectal carcinomas. Mitomycin C acts as a DNA alkylating agent that cross-links DNA to inhibit cancer cell proliferation. The PIPAC delivery method uses a pressurized aerosol to enhance drug penetration into peritoneal tumor tissues. Systemic FOLFIRI provides cytotoxic effects through thymidylate synthase and topoisomerase I inhibition, while bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis.
- Other names
- Mitomycin C PIPAC - FOLFIRI CombinationMMC-PIPAC + FOLFIRI + bevacizumab
02
Targets
Beyond the preview
Go deeper on mitomycin + fluorouracil + irinotecan + leucovorin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin + fluorouracil + irinotecan + leucovorin + bevacizumab.